CS-045 is a new oral antidiabetic agent that was effective in insulin-resistant diabetic animal models, including the KK mouse, the ob/ob mouse, and the Zucker fatty rat. CS-045 was not effective in the streptozocin-treated mouse, an insulin-deficient diabetic animal model. In fed KK mice, CS-045 lowered the plasma glucose levels in a dosedependent manner after a single oral administration, and the hypoglycemic effect lasted for at least 18 h. In normal rats, however, plasma glucose levels were not changed after administration of CS-045. CS-045 when given chronically (2 wk) to diabetic KK and ob/ob mice as a 0.2% food admixture dramatically improved hyperglycemia, hyperinsulinemia, and hypertriglyceridemia to near-normal values and decreased plasma lactate, free fatty acid, and ketone body levels without reducing food intake or body weight. In the obese Zucker fatty rat, oral administration of CS-045 had a similar effect in lowering plasma glucose, insulin, triglyceride, free fatty acid, lactate, and ketone body levels. The CS-045–treated Zucker fatty rats showed increased glucose tolerance and decreased insulin secretion in response to oral glucose. After 9 days of treatment, insulin binding to adipocyte plasma membranes from both CS-045-treated Zucker fatty rats and KK mice was increased. Furthermore, 2-deoxyglucose uptake in CS-045-treated adipocytes was increased and the insulin dose-response curve was shifted to the left. These findings suggest that CS-045 increases not only insulin sensitivity but also insulin responsiveness. Based on its pharmacological profile, CS-045 is a new orally effective antidiabetic agent that may reduce abnormalities of glucose and lipid metabolism in obese and non-insulin-dependent diabetes mellitus patients with insulin resistance.
Skip Nav Destination
Article navigation
Original Articles|
November 01 1988
Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats
Toshihiko Fujiwara;
Toshihiko Fujiwara
Biological Research Laboratories and Medicinal Chemical Research Laboratories, Sankyo Company
Tokyo, Japan
Search for other works by this author on:
Shinji Yoshioka;
Shinji Yoshioka
Biological Research Laboratories and Medicinal Chemical Research Laboratories, Sankyo Company
Tokyo, Japan
Search for other works by this author on:
Takao Yoshioka;
Takao Yoshioka
Biological Research Laboratories and Medicinal Chemical Research Laboratories, Sankyo Company
Tokyo, Japan
Search for other works by this author on:
Izumi Ushiyama;
Izumi Ushiyama
Biological Research Laboratories and Medicinal Chemical Research Laboratories, Sankyo Company
Tokyo, Japan
Search for other works by this author on:
Hiroyoshi Horikoshi
Hiroyoshi Horikoshi
Biological Research Laboratories and Medicinal Chemical Research Laboratories, Sankyo Company
Tokyo, Japan
Search for other works by this author on:
Address correspondence and reprint requests to Hiroyoshi Horikoshi, PhD, Biological Research Laboratories, Sankyo Company, Ltd., No. 2–58,1-Chome, Hiromachi, Shinagawa-ku, Tokyo 140, Japan.
Diabetes 1988;37(11):1549–1558
Article history
Received:
December 14 1987
Revision Received:
May 27 1988
Accepted:
May 27 1988
PubMed:
3053303
Citation
Toshihiko Fujiwara, Shinji Yoshioka, Takao Yoshioka, Izumi Ushiyama, Hiroyoshi Horikoshi; Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats. Diabetes 1 November 1988; 37 (11): 1549–1558. https://doi.org/10.2337/diab.37.11.1549
Download citation file:
227
Views